Pt Jayamas Medica Industri Tbk · IDX:OMED

Pt Jayamas Medica Industri Tbk — Investor Presentation (July 2025)

28 slides from Pt Jayamas Medica Industri Tbk's investor presentation, July 2025

  1. Slide 1: PT Jayamas Medica Industri Tbk (OMED IJ) Company Update 1H 2025

    PT Jayamas Medica Industri Tbk (OMED IJ) Company Update 1H 2025 July 2025

  2. Slide 2: Table of Contents

    Table of Contents 0 Executive Summary 1 Company Overview 2 Business Overview 3 Key Investment Highlights 4 Growth Strategies 5 Financials & Operations

  3. Slide 3: Executive Summary

    EXECUTIVE SUMMARY

  4. Slide 4: Executive Summary

    EXECUTIVE SUMMARY PT Jayamas Medica Industri Tbk (OMED or “The Company”) founded in early 2000s. Since then, OMED has become a market leader in the Indonesian medical equipment and supplies market with a diverse product offering product portfolio consists of around 3,550 Active SKUs, supported by a

  5. Slide 5: Company Overview

    COMPANY OVERVIEW

  6. Slide 6: Management Profile

    Management Profile Board of Commissioners Dr. Yacobus Jemmy Hartanto, MPH Siane Soetanto David A. Worth President Commissioner Commissioner Independent Commissioner Years of Experience: 44 Years of Experience: 38 Years of Experience: 41 Universitas Mahidol Udayana University Dr. Jemmy Hartanto is th

  7. Slide 7: Shareholders Structure

    Shareholders Structure Treasury Dr. Jemmy Hartanto, MPH Siane Soetanto Public Shares Shares (2) 50.00% 50.00% PT Intisumber Hasilsempurna – IHS 83.30% 0.93% 0.90% 14.84% 0,04% PT Jayamas Medica Industri Tbk – JMI (M edical Equipm ent & Supplies M anufacturer) *Listed Company 51.00% 99.00% PT Jayamas

  8. Slide 8: Key Milestones

    Key Milestones Our Key Accomplishment Since 1992 1992 2000 2002 2006 2016 2022 2023 2024 - Present VENTURED KRIAN GROUND JOINT Total Area Distribution 2,200 sqm BREAKING VENTURES Business New Facility with Foreign Entities Batang, Central Java KRIAN EXPANSION Total Area 8,000 sqm MOJOAGUNG IPO EXPAN

  9. Slide 9: Business Overview

    BUSINESS OVERVIEW

  10. Slide 10: Product Portfolio

    Product Portfolio Sales by Products – 1H 2025 Antiseptic & Dialysis 11.1% Includes liquid antiseptics 16.4% and disinfectants, dialysis 11.4% fluid, swabs and antiseptic wipes and gel 4.6% Diagnostic & Equipment 5.0% Includes thermometers, digital and manual tensimeters, weight scales and others 2.3

  11. Slide 11: Product Portfolio

    Product Portfolio Sales by Products – 1H 2025 (Top 5 in Medical Disposable & Consumables) Infus Set & IV Underpad 6,8% 6,8% Syringe & Needles 23,0% Masks 9,3% Others Gloves 26,4% 28.0%

  12. Slide 12: Production Facility

    Production Facility KRIAN FACILITY MOJOAGUNG FACILITY BATANG FACILITY Krian Mojoagung Batang Year of Commencing 2002 2016 2024 Manufacturing Facilities 21,000 Sqm 67,846 Sqm 35,650 Sqm Location East Java Central Java ISO 13485 ISO 9001 ISO 13485 ISO 9001 Quality Quality Quality Quality ISO Managemen

  13. Slide 13: Prominent Customer Profile

    Prominent Customer Profile Our Major Global Customer & Revenue Contribution Each Segment 1H 2025 PRIVATE 69.8% GOVERNMENT 29.9% 0.4% EXPORT OneMed’s Diversified Revenue Structure Reflects Low Concentration Risk and Resilient Business Fundamentals

  14. Slide 14: Revenue Channels

    Revenue Channels Sales by Brands Sales by Channel Merek OneMed Government Medical Retail Distributors bodies and Facilities customers entities  Distributor with e-  Supplies all product Catalogue permits are for hospitals able to on-sell to  Supply of primarily government, while blood collection

  15. Slide 15: Key Investment Highlight

    KEY INVESTMENT HIGHLIGHT

  16. Slide 16: Competitive Advantages

    Competitive Advantages ONE STOP SHOPPING DIVERSE SALES CHANNELS 7 Product Categories Approximately 3,550 Active SKUs Retail Distributors Customers Medical Government Facilities Entities EXTENSIVE DISTRIBUTION MANUFACTURING DIVISION 1 National Distribution Center 12 Sales Offices >40% Locally Manufac

  17. Slide 17: Main Competitors' Brand

    Main Competitors’ Brand TOP- SELLING Company B Company C Company D Company E Company F Company G Company H Company I Company J PRODUCTS Face Mask  Pregnancy Test  Gauze & Woundcare   Piston Syringe   Antiseptic  Disinfectant  

  18. Slide 18: Growth Strategies

    GROWTH STRATEGIES

  19. Slide 19: Capacity and Market Expansion

    Capacity and Market Expansion KRIAN BATANG MOJOAGUNG Estimated Budget Use of Proceed Business Expansion Plan Details (IDR Billion) (IDR Billion)* Construction of Buildings, Procurement of Production Machinery New buildings in Batang, new office building in IDR 425 IDR 301 and Equipment Mojoagung, ne

  20. Slide 20: Global Partnership (Export)

    Global Partnership (Export) Riding Southeast Asia’s Export Momentum to the U.S. Level Playing Field = New Opportunity Strategic Tailwinds • As of August 2025, the U.S. now applies a uniform 19% • U.S. buyers are diversifying away from China, turning tariff to major Southeast Asian exporters: Indones

  21. Slide 21: Financial & Operations

    FINANCIAL & OPERATIONS

  22. Slide 22: Financial Overview

    Financial Overview Revenue (In Billion Rupiah) EBITDA (In Billion Rupiah) Net Profit (In Billion Rupiah) 1,886 1,739 1,737 5.3% 25.0% 21.6% 21.4% 21.1% 16.8% 17.2% 16.5% 16.7% 879.6 925.8 20.7% 14.9% 434.6 359.5 407.3 290.5 259.4 324.0 188.3 195.2 145.2 154.7 2022 2023 2024 1H24 1H25 2022 2023 2024

  23. Slide 23: Operational Highlight

    Operational Highlight Production Price Sales (in thousand units) 1H24 1H25 YoY (in IDR) 1H24 1H25 YoY (in IDR) 1H24 1H25 YoY Average Selling Sales Volume Total Sales Price Disposable & Disposable & Disposable & 754,618 805,795 6.78% 593 567 -4.45% 447,488,634 456,589,250 2.03% Consumables Consumable

  24. Slide 24: Key Performance Ratios

    Key Performance Ratios Key Ratios 2021 2022 2023 2024 1H 2024 1H 2025 Profitability Ratios Revenue Growth 11.6% -21.9% -0.1% 8.6% 8.4% 5.3% Gross Profit Margin 40.6% 35.1% 31.8% 33.1% 33.2% 33.8% EBITDA Margin 34.7% 25.0% 23.1% 21.6% 21.4% 21.1% Net Profit Margin 25.6% 16.8% 14.9% 17.2% 16.5% 16.7%

  25. Slide 25: Corporate Highlights & Public Engagements

    Corporate Highlights & Public Engagements Source: Company’s Social Media

  26. Slide 26: Corporate Highlights & Public Engagements

    Corporate Highlights & Public Engagements Source: Company’s Social Media

  27. Slide 27: Thank You

    THANK YOU PT Jayamas Medica Industri Tbk (OMED IJ)

  28. Slide 28: Contact Us

    CONTACT US ir@onemed.co.id https://www.tokopedia.com/onemed corporate.secretary@onemed.co.id https://www.onemed.co.id/ https://shopee.co.id/onemed https://omed.idx

PT Jayamas Medica Industri — Investor Presentation (July 2025) on 6ix